We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

103 hedge funds and large institutions have $505M invested in Terns Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 16

32% more funds holding

Funds holding: 78 → 103 (+25)

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

7.93% more ownership

Funds ownership: 93.9% → 101.83% (+7.9%)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

20% less capital invested

Capital invested by funds: $630M → $505M (-$125M)

69% less call options, than puts

Call options by funds: $3.35M | Put options by funds: $10.7M

Holders
103
Holders Change
+25
Holders Change %
+32.05%
% of All Funds
1.62%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
41
Increased
29
Reduced
22
Closed
16
Calls
$3.35M
Puts
$10.7M
Net Calls
-$7.38M
Net Calls Change
-$7.38M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$28.4M
2
SCM
Suvretta Capital Management
New York
+$24.6M
3
Millennium Management
Millennium Management
New York
+$14M
4
DTC
Deep Track Capital
Connecticut
+$12.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$10.9M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$15.7M
2
DCM
Driehaus Capital Management
Illinois
-$9.88M
3
VA
VR Adviser
New York
-$7.54M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$7.45M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$2.3M -$3.17M -271,842 -51%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$2.09M +$14.6K +1,253 +0.5%
SB
28
Samsara BioCapital
California
$1.77M – – –
IHAM
29
Integral Health Asset Management
New York
$1.57M +$932K +80,000 +80%
HS
30
HighVista Strategies
Massachusetts
$1.57M +$382K +32,816 +22%
N
31
Nuveen
North Carolina
$1.54M +$2.05M +176,138 New
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$1.44M -$1.9M -163,177 -50%
Norges Bank
33
Norges Bank
Norway
$1.43M +$1.91M +163,900 New
Adage Capital Partners
34
Adage Capital Partners
Massachusetts
$1.31M +$1.75M +150,000 New
Morgan Stanley
35
Morgan Stanley
New York
$1.22M -$27.3K -2,346 -2%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$1.12M +$1.26M +107,990 +530%
SSA
37
Schonfeld Strategic Advisors
New York
$1.04M +$42.9K +3,684 +3%
Charles Schwab
38
Charles Schwab
California
$1M +$1.18M +100,898 +736%
PHP
39
Parkman Healthcare Partners
Connecticut
$896K +$320K +27,425 +37%
PAMP
40
Polar Asset Management Partners
Ontario, Canada
$875K – – –
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$744K +$408K +34,975 +70%
Victory Capital Management
42
Victory Capital Management
Texas
$647K +$862K +73,930 New
Connor, Clark & Lunn Investment Management (CC&L)
43
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$632K +$702K +60,224 +503%
Swiss National Bank
44
Swiss National Bank
Switzerland
$594K +$791K +67,900 New
AI
45
Atom Investors
Texas
$539K +$113K +9,697 +19%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$507K +$675K +57,950 New
Goldman Sachs
47
Goldman Sachs
New York
$506K -$367K -31,522 -35%
TI
48
Trexquant Investment
Connecticut
$472K +$628K +53,901 New
Renaissance Technologies
49
Renaissance Technologies
New York
$466K -$606K -52,000 -49%
UBS Group
50
UBS Group
Switzerland
$464K +$552K +47,403 +836%
1
2
3 4 5

TERN Hedge Fund Activity: Q2 2023 in Review

103 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2023, worth a combined $505M — down 20% from $630M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new TERN positions and 16 closed out — a net gain of 25 holders — while 29 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $28.4M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $15.7M sold.

  • 103 institutional investors held Terns Pharmaceuticals (TERN) as of Q2 2023, up from 78 in Q1 2023.
  • Funds reported $505M of Terns Pharmaceuticals stock for Q2 2023, down 20% quarter-over-quarter.
  • 41 funds opened new Terns Pharmaceuticals positions in Q2 2023 and 16 closed out, a net change of +25 holders.
  • The largest Terns Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $28.4M added.
  • The largest Terns Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $15.7M sold.

Based on aggregated 13F filings for Q2 2023.